Datum Biotech Ltd. has announced the founding of Datum Orthobiologics Ltd. Datum Orthobiologics will focus on creating advanced biomaterials for orthopedics based on proven bone formation and tissue regeneration solutions. These bio-programmable medical devices are designed to contribute to long-term healing and regeneration of musculoskeletal components.
Datum Orthobiologics will concentrate its initial efforts on bone graft products. The unique ossification properties of Datum’s products make them ideal new entrants for spine fusion and fracture grafts in trauma. The Company is currently in a round of fund-raising.
Affiliated with Datum Biotech, Datum Orthobiologics benefits from proven and patented GLYMATRIX® technology, as well as decades of know-how and industry experience. Products featuring GLYMATRIX® technology have been used safely and effectively in over half a million clinical dental and aesthetic procedures, and are trusted by medical professionals around the globe.
Mr. Gilad Karni has been appointed CEO, Datum Orthobiologics, bringing over 20 years of experience to the Company. “We are in the exciting phase of fund-raising and initiation. I am honored to have the opportunity to be a part of this Company, secure in the knowledge that our technology works. I am sure that we can improve orthopedic healing processes, and bring relief to patients.”
Mr. Itay Itzhaky, Co-founder, Datum Biotech and Datum Orthobiologics: “GLYMATRIX®, Datum Biotech’s proprietary technology mimics the body’s natural processes. Sugars are used to cross-link collagen molecules, producing collagen matrices which can be bio-programmed and tailored to deliver a range of products of varying physical properties, customized longevity and controlled rates of degradation. We continue to create game-changing, predictable, safe products dedicated to improving patients’ lives and healthcare around the globe.”
About Datum Orthobiologics
Datum Orthobiologics was founded to provide innovative orthopedic ossification, bone formation and tissue regeneration solutions.We develop advanced biomaterials designed to improve long-term healing and regeneration of musculoskeletal components. Datum Orthobiologics is affiliated with Datum Biotech, benefiting from GLYMATRIX® technology and other patented technologies.
At Datum Orthobiologics, we utilize our unique technology, expertise and knowledge to caringly create the best possible orthopedic regeneration solutions for clinicians and patients.
For Further Information
More on the orthopedic biomaterials market in the U.S. can be found in a series of reports published by iData entitled the U.S. Market Report Suite for Orthopedic Biomaterials. This report covers the following market segments: bone graft substitutes (which is represented by allografts, demineralized bone matrix, and synthetic bone grafts), orthopedic growth factors, cellular allografts, orthopedic cell therapy, hyaluronic acid viscosupplementation, orthopedic cartilage repair and spinal machined bone allografts
The iData series on the market for orthopedic biomaterials covers the U.S. and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about orthopedic biomaterials market data or procedure data, register online or email us at firstname.lastname@example.org for an U.S. Market Report Suite for Orthopedic Biomaterials brochure and synopsis.